ReviewBioMed research international2013
Immune monitoring in cancer vaccine clinical trials: critical issues of functional flow cytometry-based assays.
Review in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- An immunocompetent, multifluorescent resource for real-time analysis of osteosarcoma progression, metastasis, and response to therapy.Science advances · 2026Article
- Mechanistic biomarkers for cancer vaccine development: from cancer cell biology to neoantigen-guided precision immunotherapy.Frontiers in cell and developmental biology · 2026Review
- Cancer vaccine trial evaluations: immunobridging and potential immunological endpoints.Immunotherapy advances · 2025Review
- Immune Landscape in Kidney Transplantation.Journal of inflammation research · 2025Review
- Development of a new cell isolation device FlowMagicTM.PloS one · 2025Article
- flowSim: Near duplicate detection for flow cytometry data.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2023Article
- Blood immune cells as potential biomarkers predicting relapse-free survival of stage III/IV resected melanoma patients treated with peptide-based vaccination and interferon-alpha.Frontiers in oncology · 2023Article
- Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Review
- Design of Personalized Neoantigen RNA Vaccines Against Cancer Based on Next-Generation Sequencing Data.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Granzyme B nanoreporter for early monitoring of tumor response to immunotherapy.Science advances · 2020Article
- Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study.Frontiers in oncology · 2020Article
- Lenalidomide improves the therapeutic effect of an interferon-α-dendritic cell-based lymphoma vaccine.Cancer immunology, immunotherapy : CII · 2019Article
- Phenotypic and functional stability of leukocytes from human peripheral blood samples: considerations for the design of immunological studies.BMC immunology · 2019Article
- Polyfunctionality of CD4Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2018Article
- The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?Human vaccines & immunotherapeutics · 2018Review
- Development of an 8-color antibody panel for functional phenotyping of human CD8+ cytotoxic T cells from peripheral blood mononuclear cells.Cytotechnology · 2018Article
- Human CD8+ CD57- TEMRA cells: Too young to be called "old".PloS one · 2017Article
- The effects of storage temperature on PBMC gene expression.BMC immunology · 2016Article
- In Silico Analysis and Experimental Validation of Active Compounds from Cichorium intybus L. Ameliorating Liver Injury.International journal of molecular sciences · 2015Article
- Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.Journal of translational medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of immune monitoring assays is essential to determine the immune responses against tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs) and their possible correlation with clinical outcome in cancer patients receiving immunotherapies. Despite the wide range of techniques used, to date these assays have not shown consistent results among clinical trials and failed to define surrogate markers of clinical efficacy to antitumor vaccines. Multiparameter flow cytometry- (FCM-) based assays combining different phenotypic and functional markers have been developed in the past decade for informative and longitudinal analysis of polyfunctional T-cells. These technologies were designed to address the complexity and functional heterogeneity of cancer biology and cellular immunity and to define biomarkers predicting clinical response to anticancer treatment. So far, there is still a lack of standardization of some of these immunological tests. The aim of this review is to overview the latest technologies for immune monitoring and to highlight critical steps involved in some of the FCM-based cellular immune assays. In particular, our laboratory is focused on melanoma vaccine research and thus our main goal was the validation of a functional multiparameter test (FMT) combining different functional and lineage markers to be applied in clinical trials involving patients with melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.